Funobactam is under clinical development by Evopoint Bioscience and currently in Phase III for Ventilator Associated Pneumonia (VAP). According to GlobalData, Phase III drugs for Ventilator Associated Pneumonia (VAP) have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Funobactam’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Funobactam overview

XNW-4107 is under development for the treatment of Gram-negative bacterial infections, urinary tract infections, hospital acquired and ventilator associated pneumonia. The drug candidate acts by targeting beta-lactamase. It is administered by intravenous route.

Evopoint Bioscience overview

Evopoint Bioscience, formerly Suzhou Sinovent Pharmaceuticals, is a biopharmaceutical company that involved in development of therapeutics for oncology, autoimmunity, and infectious diseases. The company is headquartered in Suzhou, Jiangsu, China.

For a complete picture of Funobactam’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.